Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147805 | 0.95 | HTR2C (0.68) | HTR2CKDM1AHDAC1HDAC8HDAC6 | |
| SCHEMBL3681390 | 0.93 | HTR2C (0.66) | HTR2CKDM1AHDAC1HDAC8HDAC6 | |
| SCHEMBL1847401 | 0.91 | HTR2C (0.73) | HTR2CKDM1A | |
| SCHEMBL23817068 | 0.88 | HTR2C (0.59) | HTR2CKDM1A | |
| SCHEMBL26154113 | 0.85 | HTR2C (0.56) | HTR2CKDM1AHDAC1HDAC8HDAC6 | |
| SCHEMBL8767842 | 0.85 | HTR2C (0.56) | HTR2CKDM1AHDAC1HDAC8HDAC6 | |
| Cyanide SCHEMBL27770959 | 0.84 | HTR2C (0.66) | HTR2CKDM1A | |
| SCHEMBL431853 | 0.83 | HTR2C (0.50) | HTR2CKDM1ACNR2 | |
| SCHEMBL28604973 | 0.83 | CNR2 (0.63) | HTR2CESR2CNR2 | |
| SCHEMBL23059786 | 0.83 | HTR2C (0.54) | HTR2CKDM1AHDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2022038365-A9 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | SITRYX THERAPEUTICS LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| CN-108699048-A | Oxadiazolamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2018-10-23 | — | — | CN | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299072-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNA5, KCNH1, KCNK5 | HTR2C 3081/4885ESR2 4173/4885KDM1A 196/4885 |
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | HTR2C 917/4885ESR2 548/4885KDM1A 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.